Drug Discovery

#Covid-19 #Drug development #Pharmaceuticals #R&D

Pharmaceutical industry warned not to undo pandemic advances 

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online… Read More

#News

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News

#Biologics / Biotechnology #Cell painting #Collaboration #Drug discovery #Phenomics #Podcast

Recipe for success: collaboration in drug discovery – podcast 

The latest free-to-listen DDW podcast episode is titled “Recipe for success: collaboration in drug discovery”. It covers three articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas.  These articles are titled: “Why collaboration matters and… Read More

#Editor's Choice #News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Deriving context from immunological data with flow cytometry – Webinar

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

Blood cells
#Drug development #Healthcare

Novartis update on sickle cell treatment in England and Wales 

Novartis has announced that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA), which the company says not only helps with sickle cell disease (SCD), but also demonstrates a commitment to supporting health equity for a community that has been historically underserved,… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA

AstraZeneca collaboration to develop RNA therapeutics  

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More

#News

#Cancer immunotherapy #Cancer research #Drug discovery #Immuno-oncology #Systems biology #Therapeutics #Webinar

Event examines emerging strategy for cancer therapeutic development 

In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).  Challenges and Opportunities in Protein Degradation, took place on… Read More

#News

#Antivirals #Covid-19 #Drug discovery

Covid-19 antiviral pill cuts hospitalisation and deaths in half

If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News

#Collaboration #Drug development #Drug discovery #Life sciences

Brooks introduces Azenta Life Sciences to advance sample solutions 

Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences. Azenta will bring together Brookes’ existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions.  “We are excited to announce the creation of Azenta as… Read More

#News

#Biopharmaceuticals #Clinical research #Drug development #Therapeutics

Antibody-mediated therapies: meeting the challenges in R&D

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion… Read More

#Editor's Choice #Exclusive Content #News

#Collaboration #Drug discovery #ELRIG #Research

Equality, diversity and inclusion at Drug Discovery 2021

The European Laboratory Research & Innovation Group (ELRIG) UK will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science… Read More

#News

#Cell and gene therapy #Drug development

From Novartis to MiroBio: CEO to lead company growth  

MiroBio has appointed Carolin Barth as CEO to lead the company through the next major stage of its growth as its lead programme, MB272, transitions into clinical development. Dr Barth’s appointment follows other recent senior appointments including Julian Hirst, formerly of Immunocore, as CFO and Lynne Murray, formerly of… Read More

#News